nodes	percent_of_prediction	percent_of_DWPC	metapath
Everolimus—kidney cancer—muscle cancer	0.822	1	CtDrD
Everolimus—MTOR—hindlimb—muscle cancer	0.00816	0.214	CbGeAlD
Everolimus—MTOR—appendage—muscle cancer	0.007	0.183	CbGeAlD
Everolimus—FKBP1A—TGF-beta Receptor Signaling—TFE3—muscle cancer	0.00305	0.0807	CbGpPWpGaD
Everolimus—MTOR—embryo—muscle cancer	0.00233	0.0609	CbGeAlD
Everolimus—MTOR—smooth muscle tissue—muscle cancer	0.00183	0.0479	CbGeAlD
Everolimus—MTOR—renal system—muscle cancer	0.00176	0.0461	CbGeAlD
Everolimus—FKBP1A—smooth muscle tissue—muscle cancer	0.00164	0.043	CbGeAlD
Everolimus—FKBP1A—renal system—muscle cancer	0.00158	0.0414	CbGeAlD
Everolimus—FKBP1A—cardiac atrium—muscle cancer	0.00142	0.0371	CbGeAlD
Everolimus—MTOR—tendon—muscle cancer	0.00137	0.036	CbGeAlD
Everolimus—MTOR—bone marrow—muscle cancer	0.00133	0.0348	CbGeAlD
Everolimus—MTOR—vagina—muscle cancer	0.00127	0.0334	CbGeAlD
Everolimus—FKBP1A—tendon—muscle cancer	0.00124	0.0323	CbGeAlD
Everolimus—FKBP1A—bone marrow—muscle cancer	0.0012	0.0313	CbGeAlD
Everolimus—MTOR—head—muscle cancer	0.00118	0.0308	CbGeAlD
Everolimus—FKBP1A—vagina—muscle cancer	0.00115	0.03	CbGeAlD
Everolimus—MTOR—testis—muscle cancer	0.00114	0.0298	CbGeAlD
Everolimus—FKBP1A—head—muscle cancer	0.00106	0.0277	CbGeAlD
Everolimus—FKBP1A—testis—muscle cancer	0.00102	0.0268	CbGeAlD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO4—muscle cancer	0.000907	0.024	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—KIDINS220—muscle cancer	0.000864	0.0229	CbGpPWpGaD
Everolimus—MTOR—FSH signaling pathway—FOXO1—muscle cancer	0.000824	0.0218	CbGpPWpGaD
Everolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—PTGS2—muscle cancer	0.000801	0.0212	CbGpPWpGaD
Everolimus—MTOR—Regulation of Telomerase—WT1—muscle cancer	0.000729	0.0193	CbGpPWpGaD
Everolimus—MTOR—Class I PI3K signaling events mediated by Akt—FOXO1—muscle cancer	0.00067	0.0177	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIDINS220—muscle cancer	0.000649	0.0172	CbGpPWpGaD
Everolimus—MTOR—IL4-mediated signaling events—HMGA1—muscle cancer	0.00064	0.017	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—WT1—muscle cancer	0.000568	0.015	CbGpPWpGaD
Everolimus—CYP3A4—renal system—muscle cancer	0.000517	0.0135	CbGeAlD
Everolimus—MTOR—Signaling by NGF—KIDINS220—muscle cancer	0.000499	0.0132	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—FOXO1—muscle cancer	0.000474	0.0125	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO4—muscle cancer	0.000442	0.0117	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—HMGA1—muscle cancer	0.00042	0.0111	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—BUB1B—muscle cancer	0.000415	0.011	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FOXO4—muscle cancer	0.000398	0.0105	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FOXO4—muscle cancer	0.000389	0.0103	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FOXO4—muscle cancer	0.000385	0.0102	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO4—muscle cancer	0.000377	0.00997	CbGpPWpGaD
Everolimus—MTOR—Leptin signaling pathway—FOXO1—muscle cancer	0.000364	0.00964	CbGpPWpGaD
Everolimus—MTOR—IRS-related events triggered by IGF1R—IGF2—muscle cancer	0.000345	0.00914	CbGpPWpGaD
Everolimus—MTOR—IGF1R signaling cascade—IGF2—muscle cancer	0.000336	0.0089	CbGpPWpGaD
Everolimus—MTOR—CXCR4-mediated signaling events—FOXO1—muscle cancer	0.000333	0.00881	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—FOXO1—muscle cancer	0.000326	0.00864	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FOXO4—muscle cancer	0.000298	0.00788	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—FOXO1—muscle cancer	0.000294	0.00778	CbGpPWpGaD
Everolimus—MTOR—BDNF signaling pathway—CNR1—muscle cancer	0.000287	0.0076	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—FOXO1—muscle cancer	0.000287	0.0076	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—FOXO1—muscle cancer	0.000285	0.00754	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FOXO4—muscle cancer	0.000285	0.00754	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—MDM2—muscle cancer	0.000284	0.00753	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FOXO4—muscle cancer	0.00028	0.00742	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—FOXO1—muscle cancer	0.000278	0.00737	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FOXO4—muscle cancer	0.000268	0.00709	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FOXO4—muscle cancer	0.000266	0.00705	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO4—muscle cancer	0.000266	0.00705	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FOXO4—muscle cancer	0.000265	0.00702	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FOXO4—muscle cancer	0.000264	0.00698	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—PTGS2—muscle cancer	0.000261	0.0069	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO4—muscle cancer	0.00026	0.00688	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—muscle cancer	0.000249	0.00658	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FOXO4—muscle cancer	0.000248	0.00657	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FOXO4—muscle cancer	0.000248	0.00657	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO4—muscle cancer	0.000248	0.00657	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FOXO4—muscle cancer	0.000246	0.00651	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FOXO4—muscle cancer	0.000244	0.00645	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FOXO4—muscle cancer	0.000243	0.00642	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FOXO4—muscle cancer	0.00023	0.00608	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—KIT—muscle cancer	0.000224	0.00593	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—FOXO1—muscle cancer	0.00022	0.00582	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO4—muscle cancer	0.00022	0.00582	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—KIT—muscle cancer	0.000219	0.00579	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—KIT—muscle cancer	0.000217	0.00574	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—muscle cancer	0.000212	0.00561	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—FOXO1—muscle cancer	0.00021	0.00557	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—FOXO1—muscle cancer	0.000208	0.00551	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—FOXO1—muscle cancer	0.000207	0.00548	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—HMGA1—muscle cancer	0.000201	0.00532	CbGpPWpGaD
Everolimus—MTOR—Insulin Signaling—FOXO1—muscle cancer	0.000199	0.00526	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—FOXO1—muscle cancer	0.000198	0.00523	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—FOXO1—muscle cancer	0.000197	0.00521	CbGpPWpGaD
Everolimus—MTOR—EGF/EGFR Signaling Pathway—FOXO1—muscle cancer	0.000197	0.00521	CbGpPWpGaD
Everolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—MDM2—muscle cancer	0.000196	0.00519	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—FOXO1—muscle cancer	0.000196	0.00518	CbGpPWpGaD
Everolimus—MTOR—LKB1 signaling events—TP53—muscle cancer	0.000196	0.00518	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—FOXO1—muscle cancer	0.000195	0.00516	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—FOXO1—muscle cancer	0.000192	0.00508	CbGpPWpGaD
Everolimus—CYP3A4—Constitutive Androstane Receptor Pathway—FOXO1—muscle cancer	0.000191	0.00506	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—KIDINS220—muscle cancer	0.000191	0.00505	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—VEGFA—muscle cancer	0.000186	0.00493	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—MDM2—muscle cancer	0.000184	0.00487	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—FOXO1—muscle cancer	0.000183	0.00485	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—FOXO1—muscle cancer	0.000183	0.00485	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—FOXO1—muscle cancer	0.000183	0.00485	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—FOXO1—muscle cancer	0.000182	0.00481	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—FOXO1—muscle cancer	0.00018	0.00477	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—FOXO1—muscle cancer	0.000179	0.00474	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—PTGS2—muscle cancer	0.000177	0.0047	CbGpPWpGaD
Everolimus—MTOR—PI-3K cascade—MDM2—muscle cancer	0.000176	0.00467	CbGpPWpGaD
Everolimus—MTOR—PI3K/AKT activation—MDM2—muscle cancer	0.000172	0.00456	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—muscle cancer	0.000172	0.00456	CbGpPWpGaD
Everolimus—MTOR—GAB1 signalosome—MDM2—muscle cancer	0.000171	0.00452	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—FOXO1—muscle cancer	0.00017	0.00449	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FOXO4—muscle cancer	0.000169	0.00447	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—KIT—muscle cancer	0.000167	0.00443	CbGpPWpGaD
Everolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—MDM2—muscle cancer	0.000167	0.00442	CbGpPWpGaD
Everolimus—MTOR—Senescence and Autophagy in Cancer—MDM2—muscle cancer	0.000167	0.00442	CbGpPWpGaD
Everolimus—MTOR—ErbB Signaling Pathway—TP53—muscle cancer	0.000163	0.00432	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—FOXO1—muscle cancer	0.000162	0.0043	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—KIT—muscle cancer	0.00016	0.00424	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—KIT—muscle cancer	0.000158	0.00418	CbGpPWpGaD
Everolimus—FKBP1A—Spinal Cord Injury—TP53—muscle cancer	0.000155	0.00411	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—KIT—muscle cancer	0.000151	0.00399	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR—KIT—muscle cancer	0.00015	0.00397	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB2—KIT—muscle cancer	0.000149	0.00395	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—KIT—muscle cancer	0.000148	0.00393	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—muscle cancer	0.000146	0.00387	CbGpPWpGaD
Everolimus—MTOR—Oncostatin M Signaling Pathway—TP53—muscle cancer	0.000141	0.00372	CbGpPWpGaD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—VEGFA—muscle cancer	0.00014	0.0037	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—KIT—muscle cancer	0.00014	0.0037	CbGpPWpGaD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—muscle cancer	0.00014	0.0037	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—KIT—muscle cancer	0.00014	0.0037	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR—KIT—muscle cancer	0.000138	0.00366	CbGpPWpGaD
Everolimus—MTOR—Signaling by EGFR in Cancer—KIT—muscle cancer	0.000137	0.00363	CbGpPWpGaD
Everolimus—MTOR—Signaling by PDGF—KIT—muscle cancer	0.000136	0.00361	CbGpPWpGaD
Everolimus—MTOR—Adaptive Immune System—CD34—muscle cancer	0.000136	0.00361	CbGpPWpGaD
Everolimus—MTOR—AMPK Signaling—TP53—muscle cancer	0.000134	0.00355	CbGpPWpGaD
Everolimus—MTOR—Signaling by SCF-KIT—MDM2—muscle cancer	0.000132	0.00349	CbGpPWpGaD
Everolimus—MTOR—B Cell Activation—KIT—muscle cancer	0.000129	0.00342	CbGpPWpGaD
Everolimus—MTOR—Downstream signaling of activated FGFR—MDM2—muscle cancer	0.000126	0.00334	CbGpPWpGaD
Everolimus—MTOR—VEGFA-VEGFR2 Pathway—VEGFA—muscle cancer	0.000125	0.00331	CbGpPWpGaD
Everolimus—MTOR—Integrated Breast Cancer Pathway—MDM2—muscle cancer	0.000125	0.00331	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—FOXO1—muscle cancer	0.000125	0.0033	CbGpPWpGaD
Everolimus—MTOR—Signaling by ERBB4—MDM2—muscle cancer	0.000124	0.00329	CbGpPWpGaD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—muscle cancer	0.000124	0.00327	CbGpPWpGaD
Everolimus—MTOR—Downstream signal transduction—MDM2—muscle cancer	0.000119	0.00314	CbGpPWpGaD
Everolimus—Convulsion—Etoposide—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—Hyponatraemia—Doxorubicin—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—MTOR—Signaling by FGFR—MDM2—muscle cancer	0.000118	0.00312	CbGpPWpGaD
Everolimus—MTOR—Signaling by VEGF—VEGFA—muscle cancer	0.000118	0.00312	CbGpPWpGaD
Everolimus—Hypertension—Etoposide—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—Pain—Vincristine—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—Constipation—Vincristine—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—Pain in extremity—Doxorubicin—muscle cancer	0.000118	0.00116	CcSEcCtD
Everolimus—MTOR—Signaling by ERBB2—MDM2—muscle cancer	0.000117	0.00311	CbGpPWpGaD
Everolimus—MTOR—DAP12 signaling—MDM2—muscle cancer	0.000117	0.00309	CbGpPWpGaD
Everolimus—Chest pain—Etoposide—muscle cancer	0.000116	0.00114	CcSEcCtD
Everolimus—Migraine—Doxorubicin—muscle cancer	0.000116	0.00114	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Etoposide—muscle cancer	0.000115	0.00114	CcSEcCtD
Everolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—MDM2—muscle cancer	0.000115	0.00305	CbGpPWpGaD
Everolimus—Pancreatitis—Methotrexate—muscle cancer	0.000115	0.00113	CcSEcCtD
Everolimus—Discomfort—Etoposide—muscle cancer	0.000115	0.00113	CcSEcCtD
Everolimus—Hypersensitivity—Dactinomycin—muscle cancer	0.000113	0.00112	CcSEcCtD
Everolimus—FKBP1A—Disease—ENO2—muscle cancer	0.000113	0.00299	CbGpPWpGaD
Everolimus—Gastrointestinal pain—Vincristine—muscle cancer	0.000112	0.00111	CcSEcCtD
Everolimus—Cardiac arrest—Doxorubicin—muscle cancer	0.000112	0.0011	CcSEcCtD
Everolimus—Pancytopenia—Methotrexate—muscle cancer	0.000111	0.0011	CcSEcCtD
Everolimus—Infection—Etoposide—muscle cancer	0.000111	0.00109	CcSEcCtD
Everolimus—Asthenia—Dactinomycin—muscle cancer	0.00011	0.00109	CcSEcCtD
Everolimus—Blood creatinine increased—Doxorubicin—muscle cancer	0.00011	0.00108	CcSEcCtD
Everolimus—MTOR—Fc epsilon receptor (FCERI) signaling—MDM2—muscle cancer	0.00011	0.00291	CbGpPWpGaD
Everolimus—MTOR—DAP12 interactions—MDM2—muscle cancer	0.00011	0.00291	CbGpPWpGaD
Everolimus—MTOR—Signaling by FGFR in disease—MDM2—muscle cancer	0.00011	0.00291	CbGpPWpGaD
Everolimus—Dysuria—Methotrexate—muscle cancer	0.00011	0.00108	CcSEcCtD
Everolimus—Neutropenia—Methotrexate—muscle cancer	0.00011	0.00108	CcSEcCtD
Everolimus—Dehydration—Doxorubicin—muscle cancer	0.000109	0.00108	CcSEcCtD
Everolimus—Thrombocytopenia—Etoposide—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—Upper respiratory tract infection—Methotrexate—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR—MDM2—muscle cancer	0.000109	0.00289	CbGpPWpGaD
Everolimus—Tachycardia—Etoposide—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—Abdominal pain—Vincristine—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—Body temperature increased—Vincristine—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—Liver function test abnormal—Doxorubicin—muscle cancer	0.000109	0.00107	CcSEcCtD
Everolimus—Skin disorder—Etoposide—muscle cancer	0.000108	0.00106	CcSEcCtD
Everolimus—Erectile dysfunction—Methotrexate—muscle cancer	0.000108	0.00106	CcSEcCtD
Everolimus—MTOR—Signaling by EGFR in Cancer—MDM2—muscle cancer	0.000108	0.00286	CbGpPWpGaD
Everolimus—Dry skin—Doxorubicin—muscle cancer	0.000108	0.00106	CcSEcCtD
Everolimus—Hyperhidrosis—Etoposide—muscle cancer	0.000108	0.00106	CcSEcCtD
Everolimus—MTOR—Signaling by PDGF—MDM2—muscle cancer	0.000107	0.00285	CbGpPWpGaD
Everolimus—Abdominal pain upper—Doxorubicin—muscle cancer	0.000107	0.00106	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—KIDINS220—muscle cancer	0.000107	0.00284	CbGpPWpGaD
Everolimus—Hypokalaemia—Doxorubicin—muscle cancer	0.000107	0.00105	CcSEcCtD
Everolimus—Breast disorder—Doxorubicin—muscle cancer	0.000106	0.00105	CcSEcCtD
Everolimus—Anorexia—Etoposide—muscle cancer	0.000106	0.00104	CcSEcCtD
Everolimus—Aspartate aminotransferase increased—Doxorubicin—muscle cancer	0.000106	0.00104	CcSEcCtD
Everolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—muscle cancer	0.000106	0.00279	CbGpPWpGaD
Everolimus—Diarrhoea—Dactinomycin—muscle cancer	0.000105	0.00104	CcSEcCtD
Everolimus—Pneumonia—Methotrexate—muscle cancer	0.000105	0.00104	CcSEcCtD
Everolimus—Nasopharyngitis—Doxorubicin—muscle cancer	0.000105	0.00103	CcSEcCtD
Everolimus—Infestation—Methotrexate—muscle cancer	0.000105	0.00103	CcSEcCtD
Everolimus—Infestation NOS—Methotrexate—muscle cancer	0.000105	0.00103	CcSEcCtD
Everolimus—Hypotension—Etoposide—muscle cancer	0.000104	0.00102	CcSEcCtD
Everolimus—Gastritis—Doxorubicin—muscle cancer	0.000104	0.00102	CcSEcCtD
Everolimus—Muscular weakness—Doxorubicin—muscle cancer	0.000104	0.00102	CcSEcCtD
Everolimus—Alanine aminotransferase increased—Doxorubicin—muscle cancer	0.000104	0.00102	CcSEcCtD
Everolimus—Renal failure—Methotrexate—muscle cancer	0.000103	0.00101	CcSEcCtD
Everolimus—FKBP1A—Disease—HMGA1—muscle cancer	0.000103	0.00272	CbGpPWpGaD
Everolimus—Abdominal distension—Doxorubicin—muscle cancer	0.000102	0.00101	CcSEcCtD
Everolimus—Stomatitis—Methotrexate—muscle cancer	0.000102	0.001	CcSEcCtD
Everolimus—MTOR—B Cell Activation—MDM2—muscle cancer	0.000102	0.00269	CbGpPWpGaD
Everolimus—Conjunctivitis—Methotrexate—muscle cancer	0.000102	0.001	CcSEcCtD
Everolimus—Influenza—Doxorubicin—muscle cancer	0.000102	0.001	CcSEcCtD
Everolimus—Dysphagia—Doxorubicin—muscle cancer	0.000102	0.001	CcSEcCtD
Everolimus—Hypersensitivity—Vincristine—muscle cancer	0.000101	0.000997	CcSEcCtD
Everolimus—Paraesthesia—Etoposide—muscle cancer	0.0001	0.000984	CcSEcCtD
Everolimus—Haematuria—Methotrexate—muscle cancer	9.97e-05	0.000982	CcSEcCtD
Everolimus—Pancreatitis—Doxorubicin—muscle cancer	9.96e-05	0.00098	CcSEcCtD
Everolimus—Dyspnoea—Etoposide—muscle cancer	9.93e-05	0.000977	CcSEcCtD
Everolimus—Somnolence—Etoposide—muscle cancer	9.9e-05	0.000974	CcSEcCtD
Everolimus—Angina pectoris—Doxorubicin—muscle cancer	9.9e-05	0.000974	CcSEcCtD
Everolimus—Hepatobiliary disease—Methotrexate—muscle cancer	9.89e-05	0.000974	CcSEcCtD
Everolimus—Epistaxis—Methotrexate—muscle cancer	9.87e-05	0.000971	CcSEcCtD
Everolimus—Asthenia—Vincristine—muscle cancer	9.86e-05	0.000971	CcSEcCtD
Everolimus—Vomiting—Dactinomycin—muscle cancer	9.78e-05	0.000963	CcSEcCtD
Everolimus—Bronchitis—Doxorubicin—muscle cancer	9.77e-05	0.000961	CcSEcCtD
Everolimus—MTOR—NGF signalling via TRKA from the plasma membrane—MDM2—muscle cancer	9.74e-05	0.00258	CbGpPWpGaD
Everolimus—Rash—Dactinomycin—muscle cancer	9.7e-05	0.000955	CcSEcCtD
Everolimus—Decreased appetite—Etoposide—muscle cancer	9.68e-05	0.000953	CcSEcCtD
Everolimus—Pancytopenia—Doxorubicin—muscle cancer	9.65e-05	0.000949	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FOXO4—muscle cancer	9.64e-05	0.00255	CbGpPWpGaD
Everolimus—Gastrointestinal disorder—Etoposide—muscle cancer	9.62e-05	0.000946	CcSEcCtD
Everolimus—Fatigue—Etoposide—muscle cancer	9.6e-05	0.000945	CcSEcCtD
Everolimus—MTOR—Senescence and Autophagy in Cancer—TP53—muscle cancer	9.58e-05	0.00254	CbGpPWpGaD
Everolimus—Constipation—Etoposide—muscle cancer	9.52e-05	0.000937	CcSEcCtD
Everolimus—Pain—Etoposide—muscle cancer	9.52e-05	0.000937	CcSEcCtD
Everolimus—MTOR—Signaling by NGF—KIT—muscle cancer	9.51e-05	0.00252	CbGpPWpGaD
Everolimus—Dysuria—Doxorubicin—muscle cancer	9.5e-05	0.000935	CcSEcCtD
Everolimus—Neutropenia—Doxorubicin—muscle cancer	9.5e-05	0.000935	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—VEGFA—muscle cancer	9.48e-05	0.00251	CbGpPWpGaD
Everolimus—Upper respiratory tract infection—Doxorubicin—muscle cancer	9.44e-05	0.000929	CcSEcCtD
Everolimus—Haemoglobin—Methotrexate—muscle cancer	9.44e-05	0.000929	CcSEcCtD
Everolimus—Diarrhoea—Vincristine—muscle cancer	9.41e-05	0.000926	CcSEcCtD
Everolimus—Hepatitis—Methotrexate—muscle cancer	9.39e-05	0.000924	CcSEcCtD
Everolimus—Haemorrhage—Methotrexate—muscle cancer	9.39e-05	0.000924	CcSEcCtD
Everolimus—Pollakiuria—Doxorubicin—muscle cancer	9.38e-05	0.000924	CcSEcCtD
Everolimus—Pharyngitis—Methotrexate—muscle cancer	9.32e-05	0.000917	CcSEcCtD
Everolimus—Urinary tract disorder—Methotrexate—muscle cancer	9.27e-05	0.000913	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FOXO4—muscle cancer	9.25e-05	0.00245	CbGpPWpGaD
Everolimus—FKBP1A—Disease—FOXO4—muscle cancer	9.21e-05	0.00244	CbGpPWpGaD
Everolimus—Urethral disorder—Methotrexate—muscle cancer	9.21e-05	0.000906	CcSEcCtD
Everolimus—Weight decreased—Doxorubicin—muscle cancer	9.19e-05	0.000905	CcSEcCtD
Everolimus—Feeling abnormal—Etoposide—muscle cancer	9.18e-05	0.000903	CcSEcCtD
Everolimus—Hyperglycaemia—Doxorubicin—muscle cancer	9.16e-05	0.000902	CcSEcCtD
Everolimus—Nausea—Dactinomycin—muscle cancer	9.14e-05	0.0009	CcSEcCtD
Everolimus—Pneumonia—Doxorubicin—muscle cancer	9.11e-05	0.000897	CcSEcCtD
Everolimus—Gastrointestinal pain—Etoposide—muscle cancer	9.11e-05	0.000896	CcSEcCtD
Everolimus—Dizziness—Vincristine—muscle cancer	9.09e-05	0.000895	CcSEcCtD
Everolimus—Infestation NOS—Doxorubicin—muscle cancer	9.06e-05	0.000891	CcSEcCtD
Everolimus—Infestation—Doxorubicin—muscle cancer	9.06e-05	0.000891	CcSEcCtD
Everolimus—Renal failure—Doxorubicin—muscle cancer	8.9e-05	0.000876	CcSEcCtD
Everolimus—Jaundice—Doxorubicin—muscle cancer	8.83e-05	0.000869	CcSEcCtD
Everolimus—Stomatitis—Doxorubicin—muscle cancer	8.83e-05	0.000869	CcSEcCtD
Everolimus—Abdominal pain—Etoposide—muscle cancer	8.8e-05	0.000867	CcSEcCtD
Everolimus—Body temperature increased—Etoposide—muscle cancer	8.8e-05	0.000867	CcSEcCtD
Everolimus—Conjunctivitis—Doxorubicin—muscle cancer	8.8e-05	0.000866	CcSEcCtD
Everolimus—Urinary tract infection—Doxorubicin—muscle cancer	8.8e-05	0.000866	CcSEcCtD
Everolimus—Eye disorder—Methotrexate—muscle cancer	8.78e-05	0.000864	CcSEcCtD
Everolimus—Vomiting—Vincristine—muscle cancer	8.74e-05	0.00086	CcSEcCtD
Everolimus—Cardiac disorder—Methotrexate—muscle cancer	8.72e-05	0.000858	CcSEcCtD
Everolimus—Rash—Vincristine—muscle cancer	8.67e-05	0.000853	CcSEcCtD
Everolimus—Dermatitis—Vincristine—muscle cancer	8.66e-05	0.000852	CcSEcCtD
Everolimus—Haematuria—Doxorubicin—muscle cancer	8.64e-05	0.00085	CcSEcCtD
Everolimus—Headache—Vincristine—muscle cancer	8.61e-05	0.000848	CcSEcCtD
Everolimus—CYP3A4—Tryptophan metabolism—MDM2—muscle cancer	8.57e-05	0.00227	CbGpPWpGaD
Everolimus—Hepatobiliary disease—Doxorubicin—muscle cancer	8.57e-05	0.000843	CcSEcCtD
Everolimus—Epistaxis—Doxorubicin—muscle cancer	8.54e-05	0.000841	CcSEcCtD
Everolimus—Angiopathy—Methotrexate—muscle cancer	8.52e-05	0.000838	CcSEcCtD
Everolimus—Sinusitis—Doxorubicin—muscle cancer	8.5e-05	0.000836	CcSEcCtD
Everolimus—Immune system disorder—Methotrexate—muscle cancer	8.48e-05	0.000835	CcSEcCtD
Everolimus—Mediastinal disorder—Methotrexate—muscle cancer	8.46e-05	0.000833	CcSEcCtD
Everolimus—Chills—Methotrexate—muscle cancer	8.43e-05	0.000829	CcSEcCtD
Everolimus—Alopecia—Methotrexate—muscle cancer	8.3e-05	0.000817	CcSEcCtD
Everolimus—MTOR—Immune System—CD34—muscle cancer	8.26e-05	0.00219	CbGpPWpGaD
Everolimus—MTOR—Cellular responses to stress—CDKN2A—muscle cancer	8.23e-05	0.00218	CbGpPWpGaD
Everolimus—Mental disorder—Methotrexate—muscle cancer	8.23e-05	0.00081	CcSEcCtD
Everolimus—Hypersensitivity—Etoposide—muscle cancer	8.21e-05	0.000808	CcSEcCtD
Everolimus—Malnutrition—Methotrexate—muscle cancer	8.17e-05	0.000804	CcSEcCtD
Everolimus—Erythema—Methotrexate—muscle cancer	8.17e-05	0.000804	CcSEcCtD
Everolimus—Haemoglobin—Doxorubicin—muscle cancer	8.17e-05	0.000804	CcSEcCtD
Everolimus—Nausea—Vincristine—muscle cancer	8.17e-05	0.000804	CcSEcCtD
Everolimus—Rhinitis—Doxorubicin—muscle cancer	8.15e-05	0.000802	CcSEcCtD
Everolimus—Hepatitis—Doxorubicin—muscle cancer	8.13e-05	0.0008	CcSEcCtD
Everolimus—Haemorrhage—Doxorubicin—muscle cancer	8.13e-05	0.0008	CcSEcCtD
Everolimus—Hypoaesthesia—Doxorubicin—muscle cancer	8.09e-05	0.000796	CcSEcCtD
Everolimus—Pharyngitis—Doxorubicin—muscle cancer	8.07e-05	0.000794	CcSEcCtD
Everolimus—Urinary tract disorder—Doxorubicin—muscle cancer	8.03e-05	0.00079	CcSEcCtD
Everolimus—Oedema peripheral—Doxorubicin—muscle cancer	8.01e-05	0.000788	CcSEcCtD
Everolimus—Dysgeusia—Methotrexate—muscle cancer	8.01e-05	0.000788	CcSEcCtD
Everolimus—Asthenia—Etoposide—muscle cancer	7.99e-05	0.000786	CcSEcCtD
Everolimus—Connective tissue disorder—Doxorubicin—muscle cancer	7.99e-05	0.000786	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—MDM2—muscle cancer	7.98e-05	0.00211	CbGpPWpGaD
Everolimus—Urethral disorder—Doxorubicin—muscle cancer	7.97e-05	0.000784	CcSEcCtD
Everolimus—Back pain—Methotrexate—muscle cancer	7.91e-05	0.000778	CcSEcCtD
Everolimus—Pruritus—Etoposide—muscle cancer	7.88e-05	0.000776	CcSEcCtD
Everolimus—Vision blurred—Methotrexate—muscle cancer	7.7e-05	0.000758	CcSEcCtD
Everolimus—Diarrhoea—Etoposide—muscle cancer	7.62e-05	0.00075	CcSEcCtD
Everolimus—Eye disorder—Doxorubicin—muscle cancer	7.6e-05	0.000748	CcSEcCtD
Everolimus—Ill-defined disorder—Methotrexate—muscle cancer	7.58e-05	0.000746	CcSEcCtD
Everolimus—Anaemia—Methotrexate—muscle cancer	7.56e-05	0.000744	CcSEcCtD
Everolimus—Flushing—Doxorubicin—muscle cancer	7.55e-05	0.000743	CcSEcCtD
Everolimus—Cardiac disorder—Doxorubicin—muscle cancer	7.55e-05	0.000743	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—PTCH1—muscle cancer	7.5e-05	0.00199	CbGpPWpGaD
Everolimus—MTOR—Signaling by NGF—MDM2—muscle cancer	7.49e-05	0.00198	CbGpPWpGaD
Everolimus—Angiopathy—Doxorubicin—muscle cancer	7.38e-05	0.000726	CcSEcCtD
Everolimus—Malaise—Methotrexate—muscle cancer	7.37e-05	0.000725	CcSEcCtD
Everolimus—Dizziness—Etoposide—muscle cancer	7.37e-05	0.000725	CcSEcCtD
Everolimus—Immune system disorder—Doxorubicin—muscle cancer	7.34e-05	0.000723	CcSEcCtD
Everolimus—Mediastinal disorder—Doxorubicin—muscle cancer	7.33e-05	0.000721	CcSEcCtD
Everolimus—Leukopenia—Methotrexate—muscle cancer	7.32e-05	0.00072	CcSEcCtD
Everolimus—Chills—Doxorubicin—muscle cancer	7.3e-05	0.000718	CcSEcCtD
Everolimus—Alopecia—Doxorubicin—muscle cancer	7.19e-05	0.000707	CcSEcCtD
Everolimus—MTOR—Integrated Breast Cancer Pathway—TP53—muscle cancer	7.16e-05	0.0019	CbGpPWpGaD
Everolimus—Cough—Methotrexate—muscle cancer	7.13e-05	0.000702	CcSEcCtD
Everolimus—Mental disorder—Doxorubicin—muscle cancer	7.12e-05	0.000701	CcSEcCtD
Everolimus—MTOR—Innate Immune System—FOXO1—muscle cancer	7.12e-05	0.00188	CbGpPWpGaD
Everolimus—Convulsion—Methotrexate—muscle cancer	7.08e-05	0.000697	CcSEcCtD
Everolimus—Vomiting—Etoposide—muscle cancer	7.08e-05	0.000697	CcSEcCtD
Everolimus—Malnutrition—Doxorubicin—muscle cancer	7.08e-05	0.000697	CcSEcCtD
Everolimus—Erythema—Doxorubicin—muscle cancer	7.08e-05	0.000697	CcSEcCtD
Everolimus—Rash—Etoposide—muscle cancer	7.02e-05	0.000691	CcSEcCtD
Everolimus—Dermatitis—Etoposide—muscle cancer	7.02e-05	0.000691	CcSEcCtD
Everolimus—Headache—Etoposide—muscle cancer	6.98e-05	0.000687	CcSEcCtD
Everolimus—Flatulence—Doxorubicin—muscle cancer	6.97e-05	0.000686	CcSEcCtD
Everolimus—Myalgia—Methotrexate—muscle cancer	6.96e-05	0.000685	CcSEcCtD
Everolimus—Chest pain—Methotrexate—muscle cancer	6.96e-05	0.000685	CcSEcCtD
Everolimus—Arthralgia—Methotrexate—muscle cancer	6.96e-05	0.000685	CcSEcCtD
Everolimus—Dysgeusia—Doxorubicin—muscle cancer	6.93e-05	0.000682	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—muscle cancer	6.91e-05	0.00068	CcSEcCtD
Everolimus—Discomfort—Methotrexate—muscle cancer	6.88e-05	0.000677	CcSEcCtD
Everolimus—Back pain—Doxorubicin—muscle cancer	6.85e-05	0.000674	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—FOXO1—muscle cancer	6.83e-05	0.00181	CbGpPWpGaD
Everolimus—Muscle spasms—Doxorubicin—muscle cancer	6.81e-05	0.00067	CcSEcCtD
Everolimus—FKBP1A—Disease—FOXO1—muscle cancer	6.81e-05	0.0018	CbGpPWpGaD
Everolimus—Vision blurred—Doxorubicin—muscle cancer	6.67e-05	0.000657	CcSEcCtD
Everolimus—Infection—Methotrexate—muscle cancer	6.63e-05	0.000652	CcSEcCtD
Everolimus—Nausea—Etoposide—muscle cancer	6.62e-05	0.000651	CcSEcCtD
Everolimus—Ill-defined disorder—Doxorubicin—muscle cancer	6.57e-05	0.000646	CcSEcCtD
Everolimus—Nervous system disorder—Methotrexate—muscle cancer	6.54e-05	0.000644	CcSEcCtD
Everolimus—Anaemia—Doxorubicin—muscle cancer	6.54e-05	0.000644	CcSEcCtD
Everolimus—Thrombocytopenia—Methotrexate—muscle cancer	6.53e-05	0.000643	CcSEcCtD
Everolimus—Agitation—Doxorubicin—muscle cancer	6.5e-05	0.00064	CcSEcCtD
Everolimus—Skin disorder—Methotrexate—muscle cancer	6.48e-05	0.000638	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FOXO4—muscle cancer	6.45e-05	0.00171	CbGpPWpGaD
Everolimus—Hyperhidrosis—Methotrexate—muscle cancer	6.45e-05	0.000635	CcSEcCtD
Everolimus—Malaise—Doxorubicin—muscle cancer	6.38e-05	0.000628	CcSEcCtD
Everolimus—Anorexia—Methotrexate—muscle cancer	6.36e-05	0.000626	CcSEcCtD
Everolimus—MTOR—Disease—ENO2—muscle cancer	6.36e-05	0.00168	CbGpPWpGaD
Everolimus—Syncope—Doxorubicin—muscle cancer	6.35e-05	0.000625	CcSEcCtD
Everolimus—Leukopenia—Doxorubicin—muscle cancer	6.34e-05	0.000624	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—CNR1—muscle cancer	6.33e-05	0.00168	CbGpPWpGaD
Everolimus—Palpitations—Doxorubicin—muscle cancer	6.26e-05	0.000616	CcSEcCtD
Everolimus—Hypotension—Methotrexate—muscle cancer	6.23e-05	0.000614	CcSEcCtD
Everolimus—Loss of consciousness—Doxorubicin—muscle cancer	6.22e-05	0.000612	CcSEcCtD
Everolimus—Cough—Doxorubicin—muscle cancer	6.18e-05	0.000608	CcSEcCtD
Everolimus—Convulsion—Doxorubicin—muscle cancer	6.13e-05	0.000604	CcSEcCtD
Everolimus—Hypertension—Doxorubicin—muscle cancer	6.11e-05	0.000601	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Methotrexate—muscle cancer	6.08e-05	0.000598	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—VEGFA—muscle cancer	6.06e-05	0.00161	CbGpPWpGaD
Everolimus—Insomnia—Methotrexate—muscle cancer	6.03e-05	0.000594	CcSEcCtD
Everolimus—Myalgia—Doxorubicin—muscle cancer	6.03e-05	0.000593	CcSEcCtD
Everolimus—Chest pain—Doxorubicin—muscle cancer	6.03e-05	0.000593	CcSEcCtD
Everolimus—Arthralgia—Doxorubicin—muscle cancer	6.03e-05	0.000593	CcSEcCtD
Everolimus—Anxiety—Doxorubicin—muscle cancer	6.01e-05	0.000591	CcSEcCtD
Everolimus—Paraesthesia—Methotrexate—muscle cancer	5.99e-05	0.00059	CcSEcCtD
Everolimus—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—muscle cancer	5.98e-05	0.000589	CcSEcCtD
Everolimus—Discomfort—Doxorubicin—muscle cancer	5.95e-05	0.000586	CcSEcCtD
Everolimus—Dyspnoea—Methotrexate—muscle cancer	5.95e-05	0.000585	CcSEcCtD
Everolimus—Somnolence—Methotrexate—muscle cancer	5.93e-05	0.000584	CcSEcCtD
Everolimus—Dry mouth—Doxorubicin—muscle cancer	5.89e-05	0.00058	CcSEcCtD
Everolimus—Dyspepsia—Methotrexate—muscle cancer	5.87e-05	0.000578	CcSEcCtD
Everolimus—Decreased appetite—Methotrexate—muscle cancer	5.8e-05	0.000571	CcSEcCtD
Everolimus—MTOR—Disease—HMGA1—muscle cancer	5.78e-05	0.00153	CbGpPWpGaD
Everolimus—Oedema—Doxorubicin—muscle cancer	5.78e-05	0.000569	CcSEcCtD
Everolimus—Gastrointestinal disorder—Methotrexate—muscle cancer	5.76e-05	0.000567	CcSEcCtD
Everolimus—Fatigue—Methotrexate—muscle cancer	5.75e-05	0.000566	CcSEcCtD
Everolimus—Infection—Doxorubicin—muscle cancer	5.74e-05	0.000565	CcSEcCtD
Everolimus—Pain—Methotrexate—muscle cancer	5.71e-05	0.000561	CcSEcCtD
Everolimus—Shock—Doxorubicin—muscle cancer	5.68e-05	0.000559	CcSEcCtD
Everolimus—Nervous system disorder—Doxorubicin—muscle cancer	5.67e-05	0.000558	CcSEcCtD
Everolimus—Thrombocytopenia—Doxorubicin—muscle cancer	5.66e-05	0.000557	CcSEcCtD
Everolimus—Tachycardia—Doxorubicin—muscle cancer	5.64e-05	0.000555	CcSEcCtD
Everolimus—MTOR—Immune System—FOXO4—muscle cancer	5.61e-05	0.00149	CbGpPWpGaD
Everolimus—Skin disorder—Doxorubicin—muscle cancer	5.61e-05	0.000552	CcSEcCtD
Everolimus—Hyperhidrosis—Doxorubicin—muscle cancer	5.58e-05	0.00055	CcSEcCtD
Everolimus—Anorexia—Doxorubicin—muscle cancer	5.51e-05	0.000542	CcSEcCtD
Everolimus—Feeling abnormal—Methotrexate—muscle cancer	5.5e-05	0.000541	CcSEcCtD
Everolimus—Gastrointestinal pain—Methotrexate—muscle cancer	5.46e-05	0.000537	CcSEcCtD
Everolimus—MTOR—Innate Immune System—KIT—muscle cancer	5.42e-05	0.00144	CbGpPWpGaD
Everolimus—Hypotension—Doxorubicin—muscle cancer	5.4e-05	0.000531	CcSEcCtD
Everolimus—Abdominal pain—Methotrexate—muscle cancer	5.27e-05	0.000519	CcSEcCtD
Everolimus—Body temperature increased—Methotrexate—muscle cancer	5.27e-05	0.000519	CcSEcCtD
Everolimus—Musculoskeletal discomfort—Doxorubicin—muscle cancer	5.26e-05	0.000518	CcSEcCtD
Everolimus—Insomnia—Doxorubicin—muscle cancer	5.22e-05	0.000514	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—KIT—muscle cancer	5.21e-05	0.00138	CbGpPWpGaD
Everolimus—Paraesthesia—Doxorubicin—muscle cancer	5.19e-05	0.000511	CcSEcCtD
Everolimus—FKBP1A—Disease—KIT—muscle cancer	5.19e-05	0.00137	CbGpPWpGaD
Everolimus—MTOR—Disease—FOXO4—muscle cancer	5.18e-05	0.00137	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—IGF2—muscle cancer	5.18e-05	0.00137	CbGpPWpGaD
Everolimus—Dyspnoea—Doxorubicin—muscle cancer	5.15e-05	0.000507	CcSEcCtD
Everolimus—Somnolence—Doxorubicin—muscle cancer	5.14e-05	0.000505	CcSEcCtD
Everolimus—Dyspepsia—Doxorubicin—muscle cancer	5.09e-05	0.0005	CcSEcCtD
Everolimus—Decreased appetite—Doxorubicin—muscle cancer	5.02e-05	0.000494	CcSEcCtD
Everolimus—Gastrointestinal disorder—Doxorubicin—muscle cancer	4.99e-05	0.000491	CcSEcCtD
Everolimus—Fatigue—Doxorubicin—muscle cancer	4.98e-05	0.00049	CcSEcCtD
Everolimus—Constipation—Doxorubicin—muscle cancer	4.94e-05	0.000486	CcSEcCtD
Everolimus—Pain—Doxorubicin—muscle cancer	4.94e-05	0.000486	CcSEcCtD
Everolimus—Hypersensitivity—Methotrexate—muscle cancer	4.92e-05	0.000484	CcSEcCtD
Everolimus—Asthenia—Methotrexate—muscle cancer	4.79e-05	0.000471	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—FOXO1—muscle cancer	4.77e-05	0.00126	CbGpPWpGaD
Everolimus—Feeling abnormal—Doxorubicin—muscle cancer	4.76e-05	0.000469	CcSEcCtD
Everolimus—Gastrointestinal pain—Doxorubicin—muscle cancer	4.72e-05	0.000465	CcSEcCtD
Everolimus—Pruritus—Methotrexate—muscle cancer	4.72e-05	0.000465	CcSEcCtD
Everolimus—MTOR—Cellular responses to stress—TP53—muscle cancer	4.58e-05	0.00121	CbGpPWpGaD
Everolimus—Abdominal pain—Doxorubicin—muscle cancer	4.57e-05	0.000449	CcSEcCtD
Everolimus—Body temperature increased—Doxorubicin—muscle cancer	4.57e-05	0.000449	CcSEcCtD
Everolimus—Diarrhoea—Methotrexate—muscle cancer	4.56e-05	0.000449	CcSEcCtD
Everolimus—Dizziness—Methotrexate—muscle cancer	4.41e-05	0.000434	CcSEcCtD
Everolimus—MTOR—Innate Immune System—MDM2—muscle cancer	4.27e-05	0.00113	CbGpPWpGaD
Everolimus—Hypersensitivity—Doxorubicin—muscle cancer	4.26e-05	0.000419	CcSEcCtD
Everolimus—Vomiting—Methotrexate—muscle cancer	4.24e-05	0.000417	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—PTCH1—muscle cancer	4.22e-05	0.00112	CbGpPWpGaD
Everolimus—Rash—Methotrexate—muscle cancer	4.21e-05	0.000414	CcSEcCtD
Everolimus—Dermatitis—Methotrexate—muscle cancer	4.2e-05	0.000414	CcSEcCtD
Everolimus—Headache—Methotrexate—muscle cancer	4.18e-05	0.000411	CcSEcCtD
Everolimus—MTOR—Immune System—FOXO1—muscle cancer	4.15e-05	0.0011	CbGpPWpGaD
Everolimus—Asthenia—Doxorubicin—muscle cancer	4.14e-05	0.000408	CcSEcCtD
Everolimus—MTOR—Adaptive Immune System—MDM2—muscle cancer	4.1e-05	0.00109	CbGpPWpGaD
Everolimus—Pruritus—Doxorubicin—muscle cancer	4.09e-05	0.000402	CcSEcCtD
Everolimus—FKBP1A—Disease—MDM2—muscle cancer	4.08e-05	0.00108	CbGpPWpGaD
Everolimus—Nausea—Methotrexate—muscle cancer	3.96e-05	0.00039	CcSEcCtD
Everolimus—Diarrhoea—Doxorubicin—muscle cancer	3.95e-05	0.000389	CcSEcCtD
Everolimus—FKBP1A—Disease—PTGS2—muscle cancer	3.94e-05	0.00104	CbGpPWpGaD
Everolimus—MTOR—Disease—FOXO1—muscle cancer	3.83e-05	0.00101	CbGpPWpGaD
Everolimus—Dizziness—Doxorubicin—muscle cancer	3.82e-05	0.000376	CcSEcCtD
Everolimus—Vomiting—Doxorubicin—muscle cancer	3.67e-05	0.000361	CcSEcCtD
Everolimus—Rash—Doxorubicin—muscle cancer	3.64e-05	0.000358	CcSEcCtD
Everolimus—Dermatitis—Doxorubicin—muscle cancer	3.64e-05	0.000358	CcSEcCtD
Everolimus—FKBP1A—Signaling Pathways—KIT—muscle cancer	3.63e-05	0.000962	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO4—muscle cancer	3.63e-05	0.000961	CbGpPWpGaD
Everolimus—Headache—Doxorubicin—muscle cancer	3.62e-05	0.000356	CcSEcCtD
Everolimus—MTOR—Signaling Pathways—CNR1—muscle cancer	3.56e-05	0.000943	CbGpPWpGaD
Everolimus—Nausea—Doxorubicin—muscle cancer	3.43e-05	0.000338	CcSEcCtD
Everolimus—MTOR—Immune System—KIT—muscle cancer	3.16e-05	0.000836	CbGpPWpGaD
Everolimus—MTOR—Disease—KIT—muscle cancer	2.92e-05	0.000772	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—IGF2—muscle cancer	2.91e-05	0.000771	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—MDM2—muscle cancer	2.86e-05	0.000757	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—FH—muscle cancer	2.74e-05	0.000726	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—FOXO1—muscle cancer	2.68e-05	0.00071	CbGpPWpGaD
Everolimus—MTOR—Immune System—MDM2—muscle cancer	2.49e-05	0.000659	CbGpPWpGaD
Everolimus—MTOR—Disease—MDM2—muscle cancer	2.3e-05	0.000608	CbGpPWpGaD
Everolimus—MTOR—Disease—PTGS2—muscle cancer	2.21e-05	0.000586	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—VEGFA—muscle cancer	2.17e-05	0.000575	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—KIT—muscle cancer	2.04e-05	0.000541	CbGpPWpGaD
Everolimus—FKBP1A—Signaling Pathways—TP53—muscle cancer	1.64e-05	0.000435	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—MDM2—muscle cancer	1.61e-05	0.000426	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—MED12—muscle cancer	1.55e-05	0.00041	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—ENO2—muscle cancer	1.41e-05	0.000374	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—VEGFA—muscle cancer	1.22e-05	0.000323	CbGpPWpGaD
Everolimus—MTOR—Signaling Pathways—TP53—muscle cancer	9.23e-06	0.000244	CbGpPWpGaD
Everolimus—CYP3A4—Metabolism—PTGS2—muscle cancer	4.92e-06	0.00013	CbGpPWpGaD
